Member Info for mulledwine

Yes -not too bad at all http://www.investegate.co.uk/Article.aspx?id=201108230700128278M

Commenting on these appointments, Graham Lay, Chief Executive Officer of 3D Diagnostic Imaging, said: "We continue to build our distributor base. Both Henry Schein and I.T.Stom are experts in the latest dental technology and have excellent distribution networks in their own geographies. We look forward to working with them in the future."

3D DIAGNOSTIC IMAGING PLC ("3D") CarieScan expands distribution capability with further appointments in the USA and for the first time, Russia 3D announces that its subsidiary CarieScan Limited ("CarieScan" or the "Company), a leading provider of Integrated Caries Management Support Systems ("CMSS"), has continued to expand its distribution capability with the agreement of heads of terms with Henry Schein, Inc. for the distribution of the Company's Caries Management Support System in the USA. 3D also announces the appointment of I.T.Stom as its exclusive distributor within Russia. CMSS comprises the CarieScan PRO, a handheld device for the early detection of tooth decay, and RemoteView, a software package which captures data gathered by the CarieScan PRO for instant display on a PC screen and for recall at a later date, allowing monitoring of the progression or regression of disease. The CMSS enables the comprehensive monitoring of tooth decay and the efficacy of the treatment being applied to treat the condition. The Directors believe the system is the world's first integrated caries management system. Henry Schein, Inc., USA Henry Schein, Inc. is the world's largest provider of health care products and services to office-based practitioners with net sales of a record $7.5 billion in 2010. Its North American Dental Business includes Henry Schein Dental (U.S.), Henry Schein Canada and Zahn Dental Laboratory (U.S.). It serves approximately 87% of the estimated 143,000 U.S. and Canadian office-based dental practices, as well as dental laboratories. I.T.Stom, Russia I.T.Stom (previously known as Medinfodent) was founded in 1992 and is a well known brand in Russia. It has grown to become a successful player in the dentistry market by distributing the latest dental technology. The company operates its own dental clinic and private education centre in Moscow.

http://www.investegate.co.uk/Article.aspx?id=201108230700128274M

Commenting on the results, John O'Higgins, Chief Executive, said: "We are very encouraged by the excellent results in the first half, delivering double-digit sales and profit growth in all four of our business segments. Trading in the weeks since our last update on 15 July has remained in line with our expectations. We continue to expect that growth rates will revert to more normal levels following the strong recovery in the second half of 2010. The focus we maintained on all aspects of our strategy continues to deliver results and we remain confident that Spectris will make good progress for the full year."

Highlights · Double-digit sales and profit increase in all segments · Strong growth in all four regions · Contribution from 2010 acquisitions ahead of expectations · Record first half operating profit and earnings per share · Cash conversion at top end of our expectations · Agreement reached to acquire Omega Engineering for $475 million · Dividend up by 15%

http://www.investegate.co.uk/Article.aspx?id=201108230700128292M

CONT. "PuriCore's emerging Wound Care business continues to grow steadily, with sales increasing each month. Bottled Vashe, now with a 12-month self-life, is popular with both customers and key opinion leaders, and we will continue to develop new packaging options for different clinical uses and will launch those in the coming quarters. Sales will begin later this year for our new distribution agreement with Misonix, further expanding our reach in the wound care market and underpinning profitability for our Wound Care division in future. Demand for a non-prescription option (over-the-counter) for our novel product increases, and we expect to launch our direct-to-consumer product for Vashe in Q4. "The combination of the significant improvement in UK recurring revenues, the sharp increase in the momentum of US Supermarket Retail rollouts, and the Misonix distribution agreement provides the Board with great confidence in the future profitability of each division individually and for the business collectively in 2012. Combined with other business opportunities that the Company is involved in developing, the Board is confident that the current business mix will deliver both robust growth and significant cash generation."

Chris Wightman, Executive Chairman of PuriCore, said: "PuriCore sales for the half-year were lower than expected though virtually level with the same period last year, resulting from delays in both the UK with NHS capital spending and in the US with supermarket retail orders delayed into Q3. "Capital orders for the UK Endoscopy business slowed as the National Health Service constrained capital spending as it started its new fiscal year; however, the Board is confident that sales will improve as the NHS fiscal year progresses. Recurring revenues for this business unit, nonetheless, increased by 28% over H1 2010 as we generate more value from our installed base in UK hospitals and drive towards greater rental income. We anticipate this trend to continue as we seek to increase the overall percentage that recurring revenues represents of our total revenues thereby insulating the business from NHS spending policy changes. "In the North American Supermarket Retail business, sales expected in Q2 were delayed into Q3 as evidenced by today's announcement of the major orders just received from two new leading retailer customers for enterprise-wide implementations and the increased pace of installations at the second largest retailer in the US. This represents further proof that customers install all their stores with our technology once the purchasing decision has been made and evidences our confidence that we will convert all of the current customer base, currently representing around 10,800 stores, to installing our systems. Furthermore, the second largest US retailer supermarket chain continues to roll out our Sterilox Systems at a faster rate through its enterprise as our product is now considered a best practice by this retailer. PuriCore recently received the first orders from one of this retailer's largest divisions, which will be the first to fully implement Sterilox across a complete division. As at 30 June 2011, 15% of this retailer's stores have Sterilox Systems. With these new orders, as previously indicated, 2011 total installations will be significantly higher than the 593 installations in 2010. Despite the challenging market environment in the US, these orders and the increase in roll out velocity provide significant confidence for 2012 installations.

Post-Period Significant Events · Received major new Supermarket Retail orders in August totalling $8.2 million representing 580 Sterilox System ("System") installations to be installed in H2 2011 (total installations for FY 2010: 593 Systems) § Two leading US supermarkets implementing Sterilox enterprise-wide: Winn-Dixie Stores of Jacksonville, Florida, and Stater Bros Markets of San Bernardino, California § First division of the second largest US supermarket retailer now initiating full regional implementation § As at 30 June 2011, 4,460 Systems installed; more than 40% of the target market is now either a PuriCore customer or is in a pilot programme with the Company · Reached agreement for the settlement of the claim against Misonix, Inc., in connection with the acquisition of Labcaire in 2009, inclusive of a distribution agreement for a private label version of PuriCore's Wound Care solution. The agreement provided for the cancellation of $1 million of commissions otherwise due to Misonix and guaranteed distribution profits totalling $2 million over the next 12 quarters thereby underpinning the profitability of this growing division.

Interim Results for the Six Months Ended 30 June 2011 MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 23 August 2011 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces its interim results for the six months ended 30 June 2011. Financial Highlights (unaudited) · H1 sales of $18.8 million, a decrease of 2% (5% at constant currency) (H1 2010: $19.1 million) § Supermarket Retail sales of $7.6 million, an increase of 6% (H1 2010: $7.2 million) - Supermarket Retail margins improved to 35.1% (H1 2010: 28.8%) as volume increased, field service team efficiency improved, and quality continued to improve § Endoscopy and Laboratory sales of $10.9 million, a decrease of 7% (12% at constant currency) (H1 2010: $11.7 million) - Recurring revenues increased 28% to $8.3 million in H1 2011 (H1 2010: $6.5 million) accounting for 76% of sales for the first six months of 2011 § Wound Care sales of $0.22 million, an increase of 24% (H1 2010: $0.18 million) · Overall gross profit margin of 29.9% for H1 2011 (H1 2010: 32.3%) before one-off charges § Supermarket Retail margins increased driven by volume, quality, and service team leverage § Endoscopy and Laboratory margins decreased (driving the Group decrease) driven primarily by volume and decreased service team leverage · Operating expenses, excluding depreciation, amortisation, non-cash share option expenses, and professional fees for the terminated Endoscopy sale, decreased 13.9% to $8.3 million (H1 2010: $9.6 million) · $3.8 million in cash as at 30 June 2011 (30 June 2010: $12.2 million) § $4.0 million available under $4.0 million facility signed during H1 § H1 2011 cash outflow from operating activities decreased 59.2% to $(1.6) million (2010: $(4.0) million)

http://www.investegate.co.uk/Article.aspx?id=201108230700148302M

Andy Duncan, chief executive of luxury car dealership HR Owen, decided to “rebase” — in other words “cut” — the dividend. At first glance, this looks strange for a company that has reported a doubling of pre-tax profit and an 18 per cent improvement in revenue. The company, which sells luxury brands ranging from Rolls-Royce to Lamborghini, is planning to move to a dividend cover of between 1½ and 2½ times. At nearly 17 times next year’s earnings, there are better ways of getting into the luxury market and cheaper ways of getting into the car market, says the Times.

Nick Buckles, Chief Executive Officer, commented: "Following a robust performance during the global recession, organic growth is accelerating in most regions and business sectors and we have a healthy pipeline of bidding opportunities, particularly in the UK government market. Our New Markets businesses (now 29% of group revenues) continue to show excellent organic growth - up 9% overall. We expect growth in Cash Solutions in developed markets (13% of group revenues) will continue to be impacted by low interest rates, but we are encouraged by recent discussions with financial institutions regarding outsourcing opportunities. At the Capital Markets Day in May this year, we highlighted our plans to invest around £200 million per year on acquisitions whilst maintaining our strict financial screening criteria. We have a strong pipeline of M&A opportunities which should come to fruition within the next six to twelve months. This pipeline, together with the recovery in growth in our existing business, gives us confidence in the outlook for the full year and into 2012. That confidence is reflected in the 8% increase in our interim dividend."

Half-Yearly Results Announcement January - June 2011 G4S, the world's leading international security solutions group, today announces its half year results for the six months to 30 June 2011. RESULTS HIGHLIGHTS * Group turnover* up 5% to £3,761 million (2010: £3,575m) * Organic turnover growth* of 5% (2010: 2%) * PBITA* up 3% to £239 million (2010: £233m) * PBITA margin* 6.4% (2010: 6.5%) * Operating cash flow generation of 60% of PBITA (2010: 72%); expect to achieve full year target of 85% * Adjusted earnings per share increased 8% to 10.0p (2010: 9.3p) at actual exchange rates and increased 10% (2010: 9.1p) at constant exchange rates * Interim dividend up 8% to 3.42 pence per share, DKK 0.2928 (2010: 3.17p/DKK 0.2877) * at constant (2011) exchange rates

http://www.investegate.co.uk/Article.aspx?id=20110823070000H0271

OUTLOOK Whilst the UK housing market remains stable we expect that it will continue to be challenging due to the overall economic situation. We continue to explore opportunities to improve the availability of mortgage finance with our key mortgage lending partners. We are particularly keen to assist a greater number of first time buyers fulfil their desire to acquire a home of their own. We have been successful in securing c. £35 million of funding from the HCA under the FirstBuy shared equity scheme which specifically focuses on assisting first time buyers to acquire a new build home. This funding represents c. 20% of the total funds allocated and will help us deliver c. 2,100 new homes across c. 290 developments nationwide during the period to March 2013. We expect the overall growth in new home sales volumes to reflect the developments in the wider economy. We anticipate legally completing a similar number of new homes during 2011 as we did in 2010. Our new site opening programme will continue to support sales and our consented landbank will assist in the delivery of new outlets over the long term. This high quality asset base provides an excellent platform for the future profitable growth of the Group. In the first half of 2011 Persimmon has made further strong progress which pays testimony to the expertise, hard work and determination of all our employees throughout the business. We remain committed to our strategic objectives of margin improvement and cash generation. As a consequence, our teams across the country will remain focussed on the basics of house building in their local markets which I am confident will deliver future success for the Group. Again, on behalf of the Board I would like to thank all our staff for all their efforts.

Nicholas Wrigley, Group Chairman said: "We remain committed to our strategic objectives of margin improvement and cash generation. As a consequence our teams across the country remain focussed on the basics of house building in their local markets which I am confident will deliver future success for the Group."

HALF YEAR RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2011 · Underlying pre-tax profit* of £59.7m up 52% (2010: £39.4m) · Earnings per share* of 15.5 pence, up 29% (2010: 12.0 pence per share) · Interim dividend of 4.0 pence per share, up 33% (2010: 3.0 pence per share) reflecting the improved underlying profitability of the business · Underlying operating margin* of 9.0% (2010: 8.0%) - continued improvement in underlying performance · Cash generation robust: £72.5m cash generated from operations (2010: £185.6m) - net borrowings** reduced to £15.2m (30 June 2010: £122.1m) · Revenues of £712.8m (2010: £776.6m) · Legal completions of 4,439 (2010: 4,657) · Average selling price*** 3.7% lower at £162,647 (2010: £168,936) due to mix change · Significant reduction in net finance costs to £4.5m (H1 2010: £22.7m) · 6.4% increase in net assets per share to 601.1p (30 June 2010: 565.1p) · Further optimisation of the Group's debt portfolio through strong liquidity: early repayment of remaining Senior Loan Notes and new 5 year £300m revolving credit facility · 10% increase in forward sales at 22 August 2011 of c. £1,005m (23 August 2010: £912m) with improving margins. Weekly sales rates from 30 June 2011 running 4% ahead of the prior year · Further strengthening of total land holdings - owned and under control landbank of 62,364 plots - 7,493 plots added since December 2010 with c. 37% successfully converted from our strategic land portfolio · FirstBuy incentive successfully launched. Persimmon secured c. 20% of available funding to support over 2,000 first time buyers to enter the market

http://www.investegate.co.uk/Article.aspx?id=201108230700128260M